Network Meta-analysis (NMA) of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Compared with other Triple Therapies for the Treatment of chronic obstructive Pulmonary Disease (COPD): A Comparison of annualized Rates of moderate and severe Exacerbations

被引：0
|
作者：
Ismaila, A. [1 ]
Haeussler, K. [2 ]
Czira, A. [3 ]
Youn, J. [4 ]
Malmenaes, M. [5 ]
Risebrough, N. [6 ]
Nassim, M. [2 ]
Sharma, R. [3 ]
Compton, C. [3 ]
Vogelmeier, C. [7 ]
Halpin, D. [8 ]
机构：
[1] Gsk, R&D Global Med, 1250 S Collegeville Rd, Collegeville, PA 19426 USA
[2] Icon Plc, Konrad Zuse Pl 11, D-81829 Munich, Germany
[3] Gsk, R&D Global Med, 980 Great West Rd, Brentford, England
[4] Icon Plc, Summit House,12 Red Lion Sq, London WC1R 4HQ, England
[5] Icon Plc, Klarabergsviadukten 90 Hus B, S-11164 Stockholm, Sweden
[6] Icon Plc, Unit400,3455 North Serv Rd, Burlington, ON L7N 3G2, Canada
[7] Philipps Univ Marburg, Dept Med Pulm & Crit Care Med, Deutsch Zentrum Lungenforsch Dzl, Klin Innere Med,Schwerpunkt Pneumol, Marburg, Germany
[8] Univ Exeter, Univ Exeter Med Sch, Coll Med & Hlth, Exeter, Devon, England
来源：
PNEUMOLOGIE | 2023年 / 77卷
关键词：
D O I：
10.1055/s-0043-1761102
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 408
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 23 条
  • [1] Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [2] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Afisi S. Ismaila
    Katrin Haeussler
    Alexandrosz Czira
    Ji-Hee Youn
    Mia Malmenäs
    Nancy A. Risebrough
    Jatin Agarwal
    Maria Nassim
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2022, 39 : 3957 - 3978
  • [3] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Ismaila, Afisi S.
    Haeussler, Katrin
    Czira, Alexandrosz
    Youn, Ji-Hee
    Malmenas, Mia
    Risebrough, Nancy A.
    Agarwal, Jatin
    Nassim, Maria
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2022, 39 (09) : 3957 - 3978
  • [4] Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [5] Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
    Jonathan Marshall
    Akanksha Sharma
    Patrick Darken
    Mario Ouwens
    Barinder Singh
    Deniz Tansey-Dwyer
    Advances in Therapy, 2023, 40 : 2549 - 2555
  • [6] Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"
    Marshall, Jonathan
    Sharma, Akanksha
    Darken, Patrick
    Ouwens, Mario
    Singh, Barinder
    Tansey-Dwyer, Deniz
    ADVANCES IN THERAPY, 2023, 40 (05) : 2549 - 2555
  • [7] A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
    Afisi S. Ismaila
    Katrin Haeussler
    Mia Malmenäs
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2023, 40 : 2556 - 2561
  • [8] A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"
    Ismaila, Afisi S.
    Haeussler, Katrin
    Malmenas, Mia
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2023, 40 (05) : 2556 - 2561
  • [9] Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC plus FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
    Hanania, Nicola A.
    Caveney, Scott
    Soule, Tedi
    Tombs, Lee
    Lettis, Sally
    Crim, Courtney
    Mannino, David M.
    Patel, Hitesh
    Boucot, Isabelle H.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1925 - 1938
  • [10] Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)
    Narendra, D.
    Baptist, A. P.
    Lee, L.
    Noorduyn, S. G.
    Liu, M.
    Igboekwe, E. E.
    Veeranki, P.
    Kahle-Wrobleski, K.
    Paczkowski, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
123